Time dependence of protective post-exposure prophylax with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques

被引:33
作者
Ferrantelli, Flavia
Buckley, Kathleen A.
Rasmussen, Robert A.
Chalmers, Alistair
Wang, Tao
Li, Pei-Lin
Williams, Alison L.
Hofmann-Lehmann, Regina
Montefiori, David C.
Cavacini, Lisa A.
Katinger, Hermann
Stiegler, Gabriela
Anderson, Daniel C.
McClure, Harold M.
Ruprecht, Ruth M.
机构
[1] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[3] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[4] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA
[5] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[6] Univ Agr Vienna, Inst Appl Microbiol, Vienna, Austria
[7] Polymun Sci Immunobiol Forsch GmbH, Vienna, Austria
关键词
post-exposure prophylaxis; passive immunization; neutralizing monoclonal antibodies; pathogenic simian-human immunodeficiency virus (SHIV); rhesus macaques; oral infection;
D O I
10.1016/j.virol.2006.07.056
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In a primate model of postnatal virus transmission, we have previously shown that I It post-exposure prophylaxis (PEP) with a triple combination of neutralizing monoclonal antibodies (nmAbs) conferred sterilizing protection to neonatal macaques against oral challenge with pathogenic simian-human immunodeficiency virus (SHIV). Here, we show that nmAbs can also partially protect SHIV-exposed newborn macaques against infection or disease, when given as 12 or 24 h PEP, respectively. This work delineates the potential and the limits of passive immunoprophylaxis with nmAbs. Even though 24 It PEP with nmAbs did not provide sterilizing immunity to neonatal monkeys, it contained viremia and protected infants from acute disease. Taken together with our results from other PEP studies, these data show that the success of passive immunization depends on the nmAb potency/dose and the time window between virus exposure and start of immunotherapy. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 44 条
[1]   A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 [J].
Armbruster, C ;
Stiegler, GM ;
Vcelar, BA ;
Jäger, W ;
Michael, NL ;
Vetter, N ;
Katinger, HWD .
AIDS, 2002, 16 (02) :227-233
[2]   Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12 [J].
Armbruster, C ;
Stiegler, GM ;
Vcelar, BA ;
Jäger, W ;
Köller, U ;
Jilch, R ;
Ammann, CG ;
Pruenster, M ;
Stoiber, H ;
Katinger, HWD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (05) :915-920
[3]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[4]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[5]   Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 [J].
Binley, JM ;
Klasse, PJ ;
Cao, YZ ;
Jones, I ;
Markowitz, M ;
Ho, DD ;
Moore, JP .
JOURNAL OF VIROLOGY, 1997, 71 (04) :2799-2809
[6]   Mucosal immunity: integration between mother and the breast-fed infant [J].
Brandtzaeg, P .
VACCINE, 2003, 21 (24) :3382-3388
[7]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[8]   Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120 [J].
Cavacini, LA ;
Samore, MH ;
Gambertoglio, J ;
Jackson, B ;
Duval, M ;
Wisnewski, A ;
Hammer, S ;
Koziel, C ;
Trapnell, C ;
Posner, MR .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (07) :545-550
[9]   Characterization of primary isolate-like variants of simian-human immunodeficiency virus [J].
Crawford, JM ;
Earl, PL ;
Moss, B ;
Reimann, KA ;
Wyand, MS ;
Manson, KH ;
Bilska, M ;
Zhou, JT ;
Pauza, CD ;
Parren, PWHI ;
Burton, DR ;
Sodroski, JG ;
Letvin, NL ;
Montefiori, DC .
JOURNAL OF VIROLOGY, 1999, 73 (12) :10199-10207
[10]   Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies [J].
Ferrantelli, F ;
Rasmussen, RA ;
Buckley, KA ;
Li, PL ;
Wang, T ;
Montefiori, DC ;
Katinger, H ;
Stiegler, G ;
Anderson, DC ;
McClure, HM ;
Ruprecht, RM .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (12) :2167-2173